Holen Sie sich die Stockscreener-App
5.95
2.94%
-0.18
Handel nachbörslich:
6.00
0.05
+0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.13
Offen:
$6.01
24-Stunden-Volumen:
31,073
Relative Volume:
0.60
Marktkapitalisierung:
$21.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.11M
KGV:
-3.8889
EPS:
-1.53
Netto-Cashflow:
$-28.18M
1W Leistung:
-4.49%
1M Leistung:
-18.94%
6M Leistung:
-51.82%
1J Leistung:
-86.05%
1-Tages-Spanne:
$5.92
$6.079
1-Wochen-Bereich:
$5.92
$6.44
52-Wochen-Spanne:
$5.3495
$44.59
Tempest Therapeutics Inc Stock (TPST) Company Profile
Firmenname
Tempest Therapeutics Inc
Sektor
Branche
Telefon
415-798-8589
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie TPST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
5.95 | 22.94M | 0 | -31.11M | -28.18M | -1.53 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-08 | Eingeleitet | Jefferies | Buy |
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks
HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World
Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Finanzdaten der Tempest Therapeutics Inc-Aktie (TPST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):